#### NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

# **Multiple Technology Appraisal (MTA)**

# Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C in children and young people aged 3-17 years

# Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or
	appeal)
<ul> <li>Manufacturers/sponsors</li> <li>Roche (peginterferon alfa 2-a, ribavirin)</li> <li>Merck (previously Schering-Plough) (peginterferon alfa 2-b, ribavirin)</li> <li>Patient/carer groups</li> <li>Action for Children</li> <li>Action for Sick Children</li> <li>Action on Hepatitis C</li> <li>Addiction Recovery Foundation</li> <li>Afiya Trust</li> <li>African HIV Policy Network</li> <li>Together for shorter lifesAVERT</li> <li>Black Health Agency</li> <li>British Liver Trust</li> <li>Children's Liver Disease Foundation</li> <li>Children's Society</li> <li>Co-infection Alliance</li> <li>Compass UK</li> </ul>	<ul> <li>General</li> <li>Board of Community Health Councils in Wales</li> <li>British National Formulary</li> <li>Care Quality Commission</li> <li>Commissioning Support Appraisals Service</li> <li>Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>Healthcare Improvement Scotland</li> <li>Medicines and Healthcare products Regulatory Agency</li> <li>National Association of Primary Care</li> <li>NHS Alliance</li> <li>NHS Commercial Medicines Unit</li> <li>NHS Confederation</li> <li>Public Health Wales NHS Trust</li> <li>Scottish Medicines Consortium</li> </ul>
<ul> <li>Counsel and Care</li> <li>Drugs Action</li> <li>Drugscope</li> <li>Equalities National Council</li> <li>GMFA - The Gay Men's Health Charity</li> <li>Haemophilia Alliance</li> <li>Haemophilia Society</li> <li>Hepatitis A –Z</li> <li>Hepatitis C Trust</li> <li>Muslim Council of Britain</li> <li>Muslim Health Network</li> <li>NAM Publications</li> <li>National AIDS Trust</li> <li>National Children's Bureau</li> </ul>	<ul> <li>N/A</li> <li>Relevant research groups</li> <li>Action on Addiction</li> <li>Foundation for Liver Research</li> <li>MRC Clinical Trials Unit</li> <li>National Institute of Health Research</li> <li>UCL Centre for Sexual Health &amp; HIV Research</li> <li>Assessment team         <ul> <li>Southampton Health Technology</li> <li>Assessment Centre</li> </ul> </li> <li>Associated Guideline Groups</li> </ul>

National Institute for Health and Clinical Excellence

Provisional matrix for the appraisal of Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C in children and young people aged 3-17 years

Issue date: March 2012

Consultees	Commentators (no right to submit or appeal)
<ul> <li>National Parent Partnership Network</li> <li>Positively UK</li> <li>South Asian Health Foundation</li> <li>Specialised Healthcare Alliance</li> <li>Terrence Higgins Trust</li> <li>Transplant Support Network</li> <li>UK Harm Reduction Alliance</li> <li>WellChild</li> <li>Youth Net</li> </ul>	<ul> <li>National Collaborating Centre for Women's and Children's Health</li> <li>Associated Public Health Groups</li> <li>TBC</li> </ul>
<ul> <li>Professional groups</li> <li>Association of Clinical Microbiologists</li> <li>Association of Medical Microbiologists</li> <li>Association of Nurses in Substance Abuse</li> <li>British Association for Sexual Health and HIV</li> <li>British Association for the Study of the Liver</li> <li>British Association for the Study of the Liver Nurses Forum</li> <li>British Liver Nurses Forum</li> <li>British Society of Gastroenterology</li> <li>British Viral Hepatitis Group</li> <li>European Association for the Treatment of Addiction UK</li> <li>Haemophilia Nurses Association</li> <li>HCV Action</li> <li>Health Protection Agency</li> <li>Hepatitis Nurse Specialist Forum</li> <li>Infection Control Nurses Association</li> <li>Medical Foundation for AIDS &amp; Sexual Health</li> <li>Royal College of General Practitioners</li> <li>Royal College of Paediatrics and Child Health</li> <li>Royal College of Paediatrics and Child Health</li> <li>Royal College of Physicians</li> <li>Royal College of Physicians</li> <li>Royal Society of Medicine — Intellectual Disabilities Forum</li> <li>Society for General Microbiology</li> </ul>	

National Institute for Health and Clinical Excellence Provisional matrix for the appraisal of Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C in children and young people aged 3-17 years Issue date: March 2012

Consultees	Commentators (no right to submit or appeal)
<ul> <li>UK Clinical Virology Network</li> <li>UK Haemophilia Centre Doctors' Organisation</li> <li>United Kingdom Clinical Pharmacy Association</li> </ul>	
Others      Department of Health     Stoke on Trent Teaching     East Riding of Yorkshire     Welsh Government	

NICE is committed to promoting equality and eliminating unlawful discrimination.

Please let us know if we have missed any important organisations from the lists contained within the matrix and which organisations we should include who have a particular focus on relevant equality issues.

#### PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

## **Definitions:**

## Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government and relevant NHS organisations in England.

National Institute for Health and Clinical Excellence

Provisional matrix for the appraisal of Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C in children and young people aged 3-17 years

Issue date: March 2012

The manufacturer/sponsor of the technology is invited to make an evidence submission, respond to consultations and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to submit a statement<sup>1</sup>, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

### **Commentators**

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Information Authority and NHS Purchasing and Supplies Agency, and the *British National Formulary*.

All non-manufacturers/sponsors commentators are invited to nominate clinical specialists or patient experts.

#### Assessment team

An independent academic group (commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist in the appraisal) prepares an Assessment Report on the health technology (a review of the clinical and cost effectiveness of the technology(ies) based on a systematic review of the literature and a review of manufacturer and sponsor submission to the Institute).

National Institute for Health and Clinical Excellence

Provisional matrix for the appraisal of Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C in children and young people aged 3-17 years

Issue date: March 2012

<sup>&</sup>lt;sup>1</sup> Non manufacturer consultees are invited to submit statements relevant to the group they are representing.